Annals of Surgery · 2003 · 186 citations · 39 references
Life SciencesBiochemistryOncologyMolecular OncologyProtein BiochemistryProteomicsCancer ProteomicsGastric CancerMuscle PathologyProtein DegradationProtein TurnoverProteolytic EnzymesMuscle Protein BreakdownMuscle Protein DegradationMuscle Protein TurnoverProteasome SystemProteolytic PathwaysSkeletal Muscle WastingUbiquitin SystemUbiquitin-proteasome Proteolysis
OBJECTIVE: To investigate the state of activation of the ATP-ubiquitin-dependent proteolytic system in the skeletal muscle of gastric cancer patients. SUMMARY BACKGROUND DATA: Muscle wasting in experimental cancer cachexia is frequently associated with hyperactivation of the ATP-dependent ubiquitin-proteasome proteolytic system. Increased muscle ubiquitin mRNA levels have been previously shown in gastric cancer patients, suggesting that this proteolytic system might be modulated also in human cancer. METHODS: Biopsies of the rectus abdominis muscle were obtained intraoperatively from 23 gastric cancer patients and 14 subjects undergoing surgery for benign abdominal diseases, and muscle ubiquitin mRNA expression and proteasome proteolytic activities were assessed. RESULTS: Muscle ubiquitin mRNA was hyperexpressed in gastric cancer patients compared to controls. In parallel, three proteasome proteolytic activities (CTL, chymotrypsin-like; TL, trypsin-like; PGP, peptidyl-glutamyl-peptidase) significantly increased in gastric cancer patients with respect to controls. Advanced tumor stage, poor nutritional status, and age more than 50 years were associated with significantly higher CTL activity but had no influence on TL and PGP activity. CONCLUSIONS: These results confirm the involvement of the ubiquitin-proteasome proteolytic system in the pathogenesis of muscle protein hypercatabolism in cancer cachexia. The observation that perturbations of this pathway in gastric cancer patients occur even before clinical evidence of body wasting supports the thinking that specific pharmacologic and metabolic approaches aimed at counteracting the upregulation of this pathway should be undertaken as early as cancer is diagnosed.
39
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Julian Adams, Vito J. Palombella, Edward A. Sausville et al. · PubMed · 1999 · 1.5K citations
Medicine, Oncology, Pharmacology +14
James L. Bailey, X Wang, Brian K. England et al. · Journal of Clinical Investigation · 1996 · 456 citations · Full text
21-TRISOMY/NORMAL MOSAICISM IN AN INTELLIGENT CHILD WITH SOME MONGOLOID CHARACTERS
ConstanceM. Clarke, C. E. Ford, J. H. Edwards et al. · The Lancet · 1963 · 438 citations